

Dated: _____

A concise explanation of relevance of the items listed on form PTO/SB/08 is in the Specification and in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is “prior art” for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

Dated: December 30, 2005

Respectfully submitted,

By *[Signature]* *FYNN BRANTSON*
(53,970)
Louis J. DelJuidice

Registration No.: 47,522
DARBY & DARBY P.C.
P.O. Box 5257
New York, New York 10150-5257
(212) 527-7712
(212) 527-7701 (Fax)
Attorneys/Agents For Applicant

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/554,254
				Filing Date	October 24, 2005
				First Named Inventor	Takao Nakajima
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	09859/0203521-USO

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA**	US-5,270,316	12-14-1993		
	AB**	US-6,489,331B1	12-03-2002		
	AC**	US-2003/0176698A1	09-18-2003		
	AD**	US-2002/0111333A1	08-15-2002		

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³	Number-Kind Code ⁵ (if known)			
	BA	EP	0884318A1	12-16-1998		
	BB	JP	10-158267	06-16-1998		
	BC	EP	0390111B1	09-14-1994		
	BD	WO	2004/011469A1	02-05-2004		
	BE	WO	03/104804A1	12-18-2003		
	BF	WO	03/097862A1	11-27-2003		
	BG	WO	03/097064A1	11-27-2003		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Communication to the Editor, Journal of Medicinal Chemistry, 1992, Vol. 35, No. 19, pp. 3578-3581	
	CB	FUMIO SUZUKI, et al., Adenosin A1 Antagonist. 3. Structure-Activity Relationships on Amelioration Against Scopolamine- or N6-((R)-Phenylisopropyl)adenosine-Induced Cognitive Disturbance, Journal of Medicinal Chemistry, 1993, 36, pp. 2508-2518.	
	CC	TEMPLE D.L. JR., et al., Substituted 6,7-Dihydroimidazo[1,2-a]purin-9 (4H)-ones, Journal of Medicinal Chemistry, 1980, 23, pp. 1188-1198.	
	CD	HIROYUKI SAWANISHI, et al., Selective Inhibitors of Cyclic AMP-Specific Phosphodiesterase: Heterocycle-Condensed Purines, Journal of Medicinal Chemistry, 1997, 40, pp. 3248-3253	
	CE	International Search Report for PCT/JP2004/005890 mailed August 24, 2004.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

W:1098 5010203	Date Considered	
-------------------	-----------------	--